# Rocket Pharmaceuticals Inc. (RCKT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.86, market value $424 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Rocket Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -40.2%** (5-yr avg -19.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -80.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -5.2%**. Each dollar of assets produces -5.2% of profit.

## Growth
- **EPS growth (1 yr): 26.4%**. Earnings per share rose 26.4%.

## Financial health
- **Current ratio: 6.38** (quick 6.38). Current assets cover the next year's liabilities 6.38 times.
- **Altman Z-score: 4.23**. A Z-score of 4.23 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Rocket Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover Rocket Pharmaceuticals Inc.; the consensus is buy, with an average price target of $8.84 (+129% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 19.5%** (YTD 10.0%, 3-mo 40.4%). The shares are up 19.5% over twelve months including dividends.
- **From 52-week high: -29.2%** (52.6% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.73** (volatility 71%). Beta of 1.73 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RCKT · Page: https://foliofundamentals.com/stocks/rckt

Not investment advice.